Merck reduces price of Stocrin for HIV/AIDS patients in least-developed countries

By Lisa Kerner

Erie, Pa., March 7 - Merck & Co., Inc. said it once again reduced the price of its HIV/AIDS medicine, Stocrin (efavirenz), in the least-developed countries of the world and those hardest hit by the epidemic.

The price of the 600 mg formulation of Stocrin is $0.76 per day down, from $0.95 per day, while the 200 mg formulation is now $0.36 per capsule, down from $0.46 per capsule, according to a company news release.

Stocrin is a non-nucleoside reverse transcriptase inhibitor used in combination treatment for HIV.

"Merck has long been a leader in efforts to broaden access to our medicines for those who need them around the world," chief executive officer and president Richard T. Clark said in the release.

"Today's price reductions reflect our commitment to improving the lives of people living with HIV/AIDS throughout the developing world. We hope to be able to reduce the price of Stocrin again in the future as we continue to achieve efficiencies in our manufacturing processes."

Merck & Co., Inc. discovers, develops, manufactures and markets vaccines and medicines to address unmet medical needs. The company is based in Whitehouse Station, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.